ABSTRACT Introduction Classical Hodgkin lymphoma (cHL) is a curable disease, with
durable remission achieved in about 80% of patients following first-line treatment. Three …

Introduction: While most patients with Hodgkin lymphoma (HL) are successfully cured with
frontline therapy, unfortunately far too many patients have primary refractory disease or …

Combination chemotherapy with or without radiation has served as the primary therapeutic
option for classic Hodgkin lymphoma (cHL), leading to durable remission in a majority of …

The treatment landscape of classical Hodgkin lymphoma (cHL) has undergone significant
changes over the past 20 years. Gradual improvements have been made in the …

Hodgkin lymphoma (HL) is traditionally considered one of the hematological malignancies
with the highest rate of cure, ranging from 70 to 90% depending on the disease and patient …

Classical Hodgkin lymphoma (cHL) is associated with excellent outcomes with standard
frontline chemotherapy or combined modality therapy. However, up to 25% of patients will …

Introduction Brentuximab vedotin (BV) and nivolumab are well tolerated and active
treatments for patients (pts) with classical Hodgkin lymphoma (cHL). These agents were …

Introduction Brentuximab vedotin (BV) and nivolumab are well tolerated and active
treatments for patients (pts) with classical Hodgkin lymphoma (cHL). These agents were …

Introduction: Hodgkin lymphoma (HL) is a B-cell-derived malignancy mostly affecting young
adults. More than 80% of patients are cured after stage-adapted first-line treatment with …

Hodgkin lymphoma is a B-cell lymphoma that currently has a cure rate of≥ 85% in patients
with early-stage disease, using first-line chemotherapy followed by involved field …